{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:03:07Z","timestamp":1790834587097,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijid.2025.108163","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T23:04:10Z","timestamp":1761433450000},"page":"108163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week study"],"prefix":"10.1016","volume":"162","author":[{"given":"Yanhua","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yebing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-5623","authenticated-orcid":false,"given":"Hai","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108163_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106898","article-title":"Pillars of long-term antiretroviral therapy success","volume":"196","author":"Taramasso","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ijid.2025.108163_bib0002","first-page":"231","article-title":"Optimizing antiretroviral therapy with bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed PLWH","volume":"46","author":"Andreoni","year":"2023","journal-title":"New Microbiol"},{"key":"10.1016\/j.ijid.2025.108163_bib0003","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1089\/aid.2020.0107","article-title":"Reasons people living with HIV might prefer oral daily antiretroviral therapy, long-acting formulations, or future HIV remission options","volume":"36","author":"Dub\u00e9","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijid.2025.108163_bib0004","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","article-title":"Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries","volume":"97","author":"Akinwunmi","year":"2021","journal-title":"Sex Trans Infect"},{"key":"10.1016\/j.ijid.2025.108163_bib0005","series-title":"HIV drug resistance: brief report 2024","year":"2024"},{"key":"10.1016\/j.ijid.2025.108163_bib0006","article-title":"Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis","volume":"77","author":"Ge","year":"2024","journal-title":"Clin Med"},{"key":"10.1016\/j.ijid.2025.108163_bib0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12977-025-00662-5","article-title":"Therapeutic efficacy of albuvirtide-based antiretroviral therapy in people living with HIV who have low-level viremia and non-AIDS-defining malignancies: two case reports","volume":"22","author":"Zhang","year":"2025","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijid.2025.108163_bib0008","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/ID9.0000000000000044","article-title":"Hepatitis C Professional Group, Chinese Medical Association, C.C.f.D. Control, and Prevention, Chinese Guidelines for the diagnosis and treatment of HIV\/AIDS (2021 edition)","volume":"2","year":"2022","journal-title":"Infect Dis Immun"},{"key":"10.1016\/j.ijid.2025.108163_bib0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","article-title":"Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV","volume":"3","author":"Dow","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2025.108163_bib0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40121-024-00961-y","article-title":"Two-drug regimens dolutegravir\/lamivudine and dolutegravir\/rilpivirine are effective with few discontinuations in US real-world settings: results from the TANDEM study","volume":"13","author":"Schneider","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2025.108163_bib0011","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/QAD.0000000000004130","article-title":"Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study","volume":"39","author":"Xie","year":"2025","journal-title":"Aids"},{"key":"10.1016\/j.ijid.2025.108163_bib0012","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2025.108163_bib0013","series-title":"P-32 Efficacy and tolerability of long-acting cabotegravir\/rilpivirine in real-world setting, 52 weeks results","author":"Antonucci","year":"2024"},{"key":"10.1016\/j.ijid.2025.108163_bib0014","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/sextrans-2020-054706","article-title":"Effect of syphilis infection on HIV acquisition: a systematic review and meta-analysis","volume":"97","author":"Wu","year":"2021","journal-title":"Sex Trans Infect"},{"key":"10.1016\/j.ijid.2025.108163_bib0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/ph17010104","article-title":"Recent advances in pyrimidine-based drugs","volume":"17","author":"Nammalwar","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijid.2025.108163_bib0016","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ijid.2025.108163_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240880","article-title":"Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia","volume":"15","author":"Wolday","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.108163_bib0018","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/JLB.4MR1019-189R","article-title":"Incomplete immune reconstitution in HIV\/AIDS patients on antiretroviral therapy: challenges of immunological non-responders","volume":"107","author":"Yang","year":"2020","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ijid.2025.108163_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1397743","article-title":"Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders","volume":"14","author":"Fan","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijid.2025.108163_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/psp4.13244","article-title":"The population pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV: assessment of alternative dosing regimens","volume":"14","author":"Punyawudho","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijid.2025.108163_bib0021","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jcph.2494","article-title":"Population pharmacokinetic analysis of dolutegravir in treatment-experienced adults living with HIV-1","volume":"64","author":"Chandasana","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2025.108163_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108459","article-title":"Drug-drug interactions that alter the exposure of glucuronidated drugs: scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance","volume":"248","author":"Miners","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"Suppl 7","key":"10.1016\/j.ijid.2025.108163_bib0023","first-page":"S205","article-title":"Effect of disease pathologies on transporter expression and function","volume":"56","author":"Atilano-Roque","year":"2016","journal-title":"J Clin Pharmacol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225003856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225003856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:33:04Z","timestamp":1766406784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225003856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"alternative-id":["S1201971225003856"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108163","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108163"}}